Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis

https://doi.org/10.17749/2070-4909.2019.12.4.255-266

Full Text:

Abstract

Aim: to conduct a comparative clinical and economic analysis of using three SYSADOA drugs containing chondroitin sulfate or modifying its biosynthesis in patients with stage II knee osteoarthritis in an outpatient setting.

Material and methods. This was a retrospective comparative study, with the inclusion of data from medical records of outpatients with stage II knee arthritis according to the Kellgren & Lawrence classification. We calculated the cost-effectiveness from the direct costs and treatment efficiency based on the dynamics of pain, functional ability of the joint according to the Lequesne index, as well as the VAS index, the WOMAC index, ultrasound results and quality of life according to the EuroQol-5D questionnaire. The medical records of patients (n = 90) with stage II knee osteoarthritis are systematized according to inclusion / exclusion criteria. All patients were divided into 3 groups: group 1 (n = 30) received chondroitin sulfate, 100 mg in 1 ml (Chondroguard® , Sotex, Russia), i /m, every other day, the first 3 injections of 100 mg each with good tolerance starting from the 4th injection of 200 mg, the course of treatment was 25 injections over 50 days; group 2 (n = 30) received an active substance-glycosaminoglycan-peptide complex (Romania), on the 1st day – 0.3 ml, on the 2nd day – 0.5 ml and then 3 times a week for 1 ml, the course of treatment – 20 injections per 44 days; group 3 (n = 30) received the active substance – bioactive concentrate from small sea fish (Romania), 1 ml per day, course of treatment – 20 injections, 20 days.

Results. It is shown that the treatment of stage II osteoarthritis of the knee with Chondroguard® is the most economically feasible in terms of the cost-effectiveness ratio (CER=9182).

Conclusion. The study results are recommended for decision making on the use of SYSADOA at the level of doctors and health care providers.

About the Authors

I. V. Sarvilina
LLC “Medical Center “Novomeditsina”
Russian Federation

Irina V. Sarvilina – MD, PhD, Clinical Pharmacologist, Chief Physician

Rostov-on-Don



A. N. Galustyan
Saint-Petersburg State Pediatric Medical University
Russian Federation

Anna N. Galustyan– MD, PhD, Associate Professor, Head of the Department of Pharmacology

Litovskaya Str., 2, St. Petersburg 194100



A. K. Hadzhidis
Saint-Petersburg State Pediatric Medical University
Russian Federation

Alexandr K. Hadzhidis – MD, PhD, Associate Professor, Department of Pharmacology

Litovskaya Str., 2, St. Petersburg 194100



I. S. Sardaryan
Saint-Petersburg State Pediatric Medical University
Russian Federation

Ivan S. Sardaryan – MD, PhD, Associate Professor, Department of Pharmacology

Scopus Author ID: https://www.scopus.com/authid/detail.uri?authorId=57200672112

Litovskaya Str., 2, St. Petersburg 194100



N. V. Lavrov
Saint-Petersburg State Pediatric Medical University
Russian Federation

Nikanor V. Lavrov – MD, PhD, Associate Professor, Department of Pharmacology

Scopus Author ID: 6603540895
RISIN SPIN-code: 8721-5300
Author ID: 532935

Litovskaya Str., 2, St. Petersburg 194100



O. A. Gromova
Saint-Petersburg State Pediatric Medical University; Federal Research Center “Informatics and Management of the Russian Academy of Sciences
Russian Federation

Olga A. Gromova – MD, PhD, Professor, Senior Researcher, Scientific Director of the Federal Research Center “Informatics and Management”, Russian Academy of Sciences; Leading Researcher, Center for Big Data Analysis, Moscow State University

RISIN SPIN-code: 6317-9833
Author ID: 94901
Scopus Author ID: 7003589812
WOS ID: J-4946-2017 

Litovskaya Str., 2, St. Petersburg 194100
44-2 Vavilova Str., Moscow 119333 

 



Yu. S. Prokofieva
A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation; City Clinical Hospital named after S.I. Spasokukotsky Department of Health of the City of Moscow
Russian Federation

Yulia S. Prokofieva – MD, Researcher

20-1 Delegatskaya Str., Moscow 127473
21 Vucheticha Str., Moscow 127206 



References

1. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M. et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008; 58 (1): 26-35. https://doi.org/10.1002/art.23176.

2. Murphy L., Schwartz T.A., Helmick C.G., Renner J.B. et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008; 59 (9): 1207-13. https://doi.org/10.1002/art.24021.

3. Balabanova R.M., Erdes S.F. Trends in the prevalence of rheumatic diseases in ICD-10 in the adult population of the Russian Federation over 2000-2010. Rheumatology Science and Practice. 2012; 50 (3): 10-12. (In Russ.) https://doi.org/10.14412/1995-4484-2012-702.

4. Erdes Sh.F., Folomeeva O.M. Disability of the adult population of Russia due to rheumatic diseases. Russkij medicinskij zhurnal. 2007; 15 (26): 1946-1950. (in Russ.)].

5. Litwic A., Edwards M.H., Dennison E.M., Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013; 105 (1): 185-99. https://doi.org/10.1093/bmb/lds038.

6. Neogi T., Zhang Y. Epidemiology of osteoarthritis. Rheum. Dis. Clin. N. Am. 2013; 39 (1): 1-19. https://doi.org/10.1016/j.rdc.2012.10.004.

7. Galushko E.A., Erdes S.F., Alekseyeva L.I. Osteoarthrosis in outpatient practice. Modern Rheumatology Journal. 2012; 6 (4): 66-70. (In Russ.) https://doi.org/10.14412/1996-7012-2012-766.

8. Alekseeva L.I. Time-delayed drugs in the treatment of osteoarthrosis. RMZh. 2012; 7: 389-393 (in Russ.).

9. Elovikova E.S. The intensity of lipid peroxidation processes in patients with osteoarthrosis. Al’manah molodoj nauki. 2010; 3: 9-10 (in Russ.).

10. Ishijima M., Watari T., Naito K., Kaneko H. et al. Relationships between biomarkers of cartilage, bone, synovial metabolism and knee pain provide insights into the origins of pain in early knee osteoarthritis. Arthritis Res Ther. 2011; 13 (1): R22. https://doi.org/10.1186/ar3246.

11. Zaitseva E.M., Alekseeva L.I., Nasonov E.L. Pathogenesis of osteoarthritis and substantiation of the use of strontium ranelate. Rheumatology Science and Practice. 2013; 51 (6): 696-702]. http://dx.doi.org/10.14412/1995-4484-2013-696-702.

12. Clinical Pharmacology. National leadership. Edited by Belousov Yu.B., Lepakhin V.K., Kukes V.G., Petrov V.I. Moscow. 2009. (in Russ.).

13. Savelova E.E., Majko O.Yu. Rational therapy of osteoarthritis on an outpatient basis. Klinicist. 2012; 3-4: 67-72. (in Russ.).

14. Shostak N.A., Pravdyuk N.G., Klimenko A.A. Osteoarthrosis new features of delayed-effect symptom-modifying therapy. Klinicist. 2013; 3-4: 93-97. (in Russ.).

15. Rozendaal R.M., Koes B.W., van Osch G.J., Uitterlinden E.J. et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med. 2008; 148 (4): 268-77. https://doi.org/10.7326/0003-4819-148-4-200802190-00005.

16. Jordan K.M., Arden N.K., Doherty M. et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Ann Rheum Dis. 2003; 62 (12): 1145-55. https://doi.org/10.1136/ard.2003.011742.

17. Voloshin V.P., Eremin A.V., Sankaranarayanan S.A. et al. A study of the effectiveness of the drug Chondrogard (chondroitin sulfate) in patients with osteoarthritis. Trudnyj pacient. 2015; 13 (3): 2932. (in Russ.).

18. Honvo G., Bruyère O., Geerinck A., Veronese N., Reginster J.-Y. Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Controlled Trials. Adv. Ther. 2019; 36 (5): 1085-1099. https://doi.org/10.1007/s12325-019-00921-w.

19. Singh J.A., Noorbaloochi S., MacDonald R., Maxwell L.J. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015; 1: CD005614. https://doi.org/10.1002/14651858.CD005614.

20. A double-blind, placebo-controlled randomized trial of the efficacy and safety of the drug Chondrogard, a solution for intramuscular injection of 100 mg / ml (ZAO Soteks PharmFirma, Russia) in patients with gonarthrosis. No. KI / 1216-1. Register of approved clinical trials. [Electronic resource] http://grls.rosminzdrav.ru. Accessed: 18.10.2019. (in Russ.).

21. Murray C.J. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013; 380: 21972223. https://doi.org/10.1016/S0140-6736(12)61689-4.

22. Vos T. et al. Years lived with disability (YLDs) for 1,160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380:2163–2196. https://doi.org/10.1016/S0140-6736(12)61729-2.

23. On approval of the industry standard “clinical and economic research. General Provisions”: Order No. 163 of the Ministry of Health of the Russian Federation of 05.27.2011. (in Russ.).

24. Smirnov AV. Atlas of x-ray diagnosis of primary osteoarthritis. Moscow. 2010. (in Russ.).

25. Zhang W., Doherty M., Peat G. et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann.Rheum. Dis. 2010; 69 (3): 483-9. https://doi.org/10.1136/ard.2009.113100.

26. The state register of maximum selling prices. [Electronic resource]. URL: http://grls.rosminzdrav.ru. Accessed: 21.10.2019.

27. Analytical materials dedicated to the pharmaceutical markets of Russia and the CIS [Electronic resource]. URL: https://www.iqvia.com/ru-ru/locations/russia. Accessed: 21.10.2019.

28. Decree of the Government of the Russian Federation of December 10, 2018 No. 1506 “On the program of state guarantees of free medical care for citizens for 2019 and for the planning period 2020 and 2021”. Electronic resource]. URL: http://government.ru/docs/35025/. Accessed: 21.10.2019.

29. Tariff agreement on the payment of medical assistance for compulsory health insurance in the Rostov region. Electronic resource]. URL: http://rostov-tfoms.ru/dokumenty/normativnaya-baza/tarifnoe-soglashenie. Accessed: 21.10.2019.


For citation:


Sarvilina I.V., Galustyan A.N., Hadzhidis A.K., Sardaryan I.S., Lavrov N.V., Gromova O.A., Prokofieva Yu.S. Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2019;12(4):255-266. (In Russ.) https://doi.org/10.17749/2070-4909.2019.12.4.255-266

Views: 310


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)